On September 25, the 2025 Shenyang-Korea Investment and Trade Expo opened grandly. Shenyang DASAN Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “DASAN Pharmaceutical”) showcased its achievements in the pharmaceutical field at the expo.

As a specialized pharmaceutical R&D enterprise, DASAN Pharmaceutical systematically displayed its multiple drug development achievements during the expo, with core team members providing detailed technical explanations.

At the start of the expo, relevant municipal leaders visited the DASAN Pharmaceutical booth to learn about the company's progress in drug R&D, MAH project advancement, and international cooperation.

Subsequently, the company's General Manager delivered a keynote speech at a forum, comprehensively introducing DASAN Pharmaceutical's technological advantages and development strategy, which garnered positive attention from the attending guests. Regarding the strategic advancement of MAH self-held projects, DASAN Pharmaceutical has achieved substantial results. The company not only features products like Telmisartan Amlodipine Tablets—a product with clear clinical value and market prospects due to its significant advantages in hypertension treatment—but has also strategically laid out a series of potential products targeting geriatric and chronic diseases based on market demands. The steady progress of these self-held projects fully demonstrates the company's comprehensive capabilities in project initiation, R&D management, quality control, and future commercial operations.

(Mr. Yan Dong, General Manager of Shenyang DASAN Pharmaceutical Technology Co., Ltd.)

While advancing international cooperation, the DASAN Pharmaceutical R&D team also engaged in in-depth technical exchanges with several domestic pharmaceutical companies, jointly exploring opportunities for drug development collaboration.

DASAN Pharmaceutical actively participated in several professional business matching sessions organized by the expo. During the exhibition, the company held professional discussions with multiple well-known pharmaceutical companies, R&D institutions, and investment firms.

(Dr. Li Qijun, R&D Center Director of Shenyang DASAN Pharmaceutical Technology Co., Ltd.)